Source:http://linkedlifedata.com/resource/pubmed/id/12862438
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
4
|
pubmed:dateCreated |
2003-7-16
|
pubmed:abstractText |
To gain insight into the strategy to target PBR ligand-drug conjugates to brain tumors, novel N-imidazopyridinacetyl-melphalan conjugates and the corresponding ethyl esters have been prepared and evaluated for their cytotoxicity in melphalan-sensitive human (SF126, SF188) and rat (RG-2) glioma cell lines. These conjugates exhibited PBR binding affinity with IC(50) values ranging from 57 and 2614 nM. By a computational approach it can be predicted that these conjugates possess significant brain penetration. The stability of the conjugates in 0.05 M phosphate buffer at pH 7.4 and, in some cases, in dilute human serum solution was determined. All the ethyl ester derivatives were stable in 0.05 M phosphate buffer at pH 7.4 and their half-lives exceeded 28 h. Conversely, under the same conditions, the corresponding acids were found to undergo a fast cleavage within a few minutes. HPLC-MS analysis of the mixture from degradation in buffer and physiological medium of the representative cases allowed the identification of their main degradation products. A plausible degradation pathway accounting for the available experimental data is presented.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Antimetabolites, Antineoplastic,
http://linkedlifedata.com/resource/pubmed/chemical/Isoquinolines,
http://linkedlifedata.com/resource/pubmed/chemical/Ligands,
http://linkedlifedata.com/resource/pubmed/chemical/Melphalan,
http://linkedlifedata.com/resource/pubmed/chemical/PK 11195
|
pubmed:status |
MEDLINE
|
pubmed:issn |
1043-1802
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
14
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
830-9
|
pubmed:dateRevised |
2006-11-15
|
pubmed:meshHeading |
pubmed-meshheading:12862438-Animals,
pubmed-meshheading:12862438-Antimetabolites, Antineoplastic,
pubmed-meshheading:12862438-Brain Neoplasms,
pubmed-meshheading:12862438-Cell Line, Tumor,
pubmed-meshheading:12862438-Drug Delivery Systems,
pubmed-meshheading:12862438-Glioma,
pubmed-meshheading:12862438-Humans,
pubmed-meshheading:12862438-Inhibitory Concentration 50,
pubmed-meshheading:12862438-Isoquinolines,
pubmed-meshheading:12862438-Ligands,
pubmed-meshheading:12862438-Melphalan,
pubmed-meshheading:12862438-Models, Chemical,
pubmed-meshheading:12862438-Molecular Structure,
pubmed-meshheading:12862438-Time Factors
|
pubmed:articleTitle |
Peripheral benzodiazepine receptor ligand-melphalan conjugates for potential selective drug delivery to brain tumors.
|
pubmed:affiliation |
Dipartimento Farmaco-Chimico, Facoltà di Farmacia, Università degli Studi di Bari, Via Orabona 4, 70125 Bari, Italy. trapani@farmchim.uniba.it
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|